Electroporation-based cytokine gene therapy is currently in Phase II development against skin cancer.
OncoSec Medical inked an exclusive agreement with VGXI for the process development and large-scale cGMP production of interleukin-12 plasmid DNA (DNA IL-12) used in OncoSec’s ElectroImmunotherapy cancer treatment. OncoSec’s cancer therapy approach involves the use of electroporation, delivered using its OncoSec Medical System (OMS) device, to transiently increase the permeability of cancer cells to chemotherapy (OMS ElectroChemtherapy) or immunotherapeutics (ElectroImmunotherapy).
The clinical-stage ElectroImmunotherapy product is an engineered DNA plasmid encoding IL-12. Three Phase II trials are ongoing in the treatment of metastatic melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma.
VGXI is a contract manufacturing organization specialized in the GMP production of DNA plasmids for use in human clinical trials. The firm offers a full spectrum of plasmid preparation services, from the manufacture of purified plasmid preparations for DNA vaccine and gene therapy research in small animals, through to preclinical plasmid production services for large animal testing, and cGMP production of injectable-grade plasmids for human clinical trials and commercial supply.
